NCT06549595 2026-03-18
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
AstraZeneca
Phase 3 Recruiting
Clinical Trials
30 trialsNCT04542824 2026-03-03
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT04663347 2026-03-03
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT05888493 2026-02-20
LEDA
Novartis
Phase 3 Active not recruiting
NCT07398638 2026-02-10
Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT07348575 2026-01-16
A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
Second Affiliated Hospital of Nanchang University
Phase 3 Enrolling by invitation
NCT04661007 2025-12-18
J-MIND
Incyte Corporation
Phase 1/2 Active not recruiting
NCT05058404 2025-09-03
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
Fondazione Italiana Linfomi - ETS
Phase 3 Active not recruiting
NCT04546620 2025-08-06
REMoDL-A
University Hospital Southampton NHS Foundation Trust
Phase 2 Active not recruiting
NCT03995147 2025-06-08
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
University of Chicago
Phase 2 Active not recruiting
NCT01865110 2025-03-05
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL
The Lymphoma Academic Research Organisation
Phase 3 Completed
NCT04566887 2025-02-18
Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma
University Health Network, Toronto
Phase 2 Recruiting
NCT06647940 2024-10-22
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
Sun Yat-sen University
Phase 2 Recruiting
NCT02633137 2024-08-30
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01843868 2024-08-07
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Australasian Leukaemia and Lymphoma Group
Phase NA Withdrawn
NCT00268853 2024-05-30
RAPID
CTI BioPharma
Phase 2 Completed
NCT03650933 2024-02-20
A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients
Nanjing Yoko Biomedical Co., Ltd.
Phase 3 Unknown
NCT04263584 2024-01-05
COPA-R-CHOP
University Hospital Muenster
Phase 2 Unknown
NCT02660710 2022-10-28
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT04058470 2022-04-14
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Sun Yat-sen University
Phase 1/2 Unknown
NCT02605694 2021-03-17
Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
SecuraBio
Phase 2 Withdrawn
NCT02890602 2020-02-20
Erythropoietin for Management of Anemia Caused by Chemotherapy
Kosin University Gospel Hospital
Phase 2 Completed
NCT03318835 2017-10-24
Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients
Fudan University
Phase 3 Unknown
NCT00554164 2017-05-05
PETAL
University Hospital, Essen
Phase 3 Completed
NCT00209209 2017-03-07
MCLelderly
European Mantle Cell Lymphoma Network
Phase 3 Unknown
NCT02487316 2016-12-30
A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib
Peking University
Phase 4 Withdrawn
NCT02792491 2016-06-09
Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over
Pusan National University Hospital
Phase 2 Unknown
NCT00774826 2011-02-15
Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma
Fondazione Italiana Linfomi - ETS
Phase 3 Unknown
NCT00466258 2009-11-25
LINFOTARGAM
PETHEMA Foundation
Phase 4 Completed
NCT00946374 2009-07-27
HD-MCL2003
Heidelberg University
Phase 2 Unknown